Potential NIH and FDA cuts could lower the number of new drugs that come to market in the next three decades, according to a ...

Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated ...

MIT researchers have developed a new theoretical framework for studying the mechanisms of treatment interactions. Their ...

The submission is supported by four Phase III clinical trials, which showed that icotrokinra demonstrated significant skin ...

The Supreme Court’s recent unanimous decision on FDA’s drug-approval authority is utterly unremarkable.

The US Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ...

Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for deucravacitinib for the treatment of adults with active psoriatic arthritis (PsA).

The Food and Drug Administration (FDA) has granted Priority Review to TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

The U.S. Food and Drug Administration's reviewers on Wednesday raised efficacy concerns over the use of Otsuka Pharma's drug ...

Johnson & Johnson (JNJ) gets FDA priority review for TAR-200 gains, a drug releasing system targeting bladder cancer. Read ...